The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte

Baojuan Han(Harbin Medical University), Qingyuan Zhang(Jiangxi University of Traditional Chinese Medicine)

Cancer Immunology Immunotherapy

March 10, 2021

10.1007/s00262-021-02898-4

Cited by 51

Related Papers

Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)

|Journal of Clinical Oncology|2021|350

Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial

|BMJ|2023|82

Ganoderic acid A exerts antitumor activity against MDA‑MB‑231 human breast cancer cells by inhibiting the Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway

|Oncology Letters|2018|44